User menu

Experimental facts supporting a red marrow uptake due to radiometal transchelation in 90Y-DOTATOC therapy and relationship to the decrease of platelet counts

Bibliographic reference Walrand, Stephan ; Barone, Raffaella ; Pauwels, Stanislas ; Jamar, François. Experimental facts supporting a red marrow uptake due to radiometal transchelation in 90Y-DOTATOC therapy and relationship to the decrease of platelet counts. In: European Journal of Nuclear Medicine and Molecular Imaging, Vol. 38, no. 7, p. 1270-1280 (2011)
Permanent URL
  1. Brans Boudewijn, Linden Ola, Giammarile Francesco, Tennvall Jan, Punt Cornelis, Clinical applications of newer radionuclide therapies, 10.1016/j.ejca.2005.12.020
  2. Flux Glenn, Bardies Manuel, Monsieurs Myriam, Savolainen Sauli, Strand Sven-Erik, Lassmann Michael, The Impact of PET and SPECT on Dosimetry for Targeted Radionuclide Therapy, 10.1078/0939-3889-00291
  3. Flux Glenn, Bardies Manuel, Chiesa Carlo, Monsieurs Myriam, Savolainen Sauli, Strand Sven-Erik, Lassmann Michael, Clinical radionuclide therapy dosimetry: the quest for the “Holy Gray”, 10.1007/s00259-007-0471-9
  4. Brans B., Bodei L., Giammarile F., Linden O., Luster M., Oyen W. J. G., Tennvall J., Clinical radionuclide therapy dosimetry: the quest for the “Holy Gray”, 10.1007/s00259-006-0338-5
  5. Sgouros George, Frey Eric, Wahl Richard, He Bin, Prideaux Andrew, Hobbs Robert, Three-Dimensional Imaging-Based Radiobiological Dosimetry, 10.1053/j.semnuclmed.2008.05.008
  6. Stabin Michael G., Brill A. Bertrand, State of the Art in Nuclear Medicine Dose Assessment, 10.1053/j.semnuclmed.2008.05.005
  7. Barone R, Borson-Chazot F, Valkema R, Walrand S, Chauvin F, Gogou L, et al. Patient-specific dosimetry in predicting renal toxicity with (90)Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship. J Nucl Med 2005;46:99S–106S.
  8. Wessels B. W., Konijnenberg M. W., Dale R. G., Breitz H. B., Cremonesi M., Meredith R. F., Green A. J., Bouchet L. G., Brill A. B., Bolch W. E., Sgouros G., Thomas S. R., MIRD Pamphlet No. 20: The Effect of Model Assumptions on Kidney Dosimetry and Response--Implications for Radionuclide Therapy, 10.2967/jnumed.108.053173
  9. Pauwels S, Barone R, Walrand S, Borson-Chazot F, Valkema R, Kvols LK, et al. Practical dosimetry of peptide receptor radionuclide therapy with (90)Y-labeled somatostatin analogs. J Nucl Med 2005;46:92S–8S.
  10. Cremonesi M, Ferrari M, Bodei L, Tosi G, Paganelli G. Dosimetry in peptide radionuclide receptor therapy: a review. J Nucl Med 2006;47:1467–75.
  11. Forrer Flavio, Krenning Eric P., Kooij Peter P., Bernard Bert F., Konijnenberg Mark, Bakker Willem H., Teunissen Jaap J. M., de Jong Marion, van Lom Kirsten, de Herder Wouter W., Kwekkeboom Dik J., Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA0,Tyr3]octreotate, 10.1007/s00259-009-1072-6
  12. Hnatowich DJ, Griffin TW, Kosciuczyk C, Rusckowski M, Childs RL, Mattis JA, et al. Pharmacokinetics of an indium-111-labeled monoclonal antibody in cancer patients. J Nucl Med 1985;26:849–58.
  13. Cremonesi Marta, Ferrari Mahila, Chinol Marco, Stabin Michael G., Grana Chiara, Prisco Gennaro, Robertson Chris, Tosi Giampiero, Paganelli Giovanni, Three-step radioimmunotherapy with yttrium-90 biotin: dosimetry and pharmacokinetics in cancer patients, 10.1007/s002590050366
  14. Meares CF, Moi MK, Diril H, Kukis DL, McCall MJ, Deshpande SV, et al. Macrocyclic chelates of radiometals for diagnosis and therapy. Br J Cancer Suppl 1990;10:21–6.
  15. Wu C., Virzi F., Hnatowich D.J., Investigations of N-linked macrocycles for 111in and 90Y labeling of proteins, 10.1016/0883-2897(92)90012-n
  16. Hnatowich DJ, Virzi F, Doherty PW. DTPA-coupled antibodies labeled with yttrium-90. J Nucl Med 1985;26:503–9.
  17. de Klerk JMH, van Dieren EB, van het Schip AD, Hoekstra A, Zonnenberg BA, van Dijk A, et al. Bone marrow absorbed dose of rhenium-186-HEDP and the relationship with decreased platelet counts. J Nucl Med 1996;37:38–41.
  18. Turner J.Harvey, Claringbold Phillip G., A phase II study of treatment of painful multifocal skeletal metastases with single and repeated dose samarium-153 ethylenediaminetetramethylene phosphonate, 10.1016/0277-5379(91)90297-q
  19. Langham WH. Radiobiological factors in manned space flight. Washington DC: National Academy Press; 1967.
  20. Hindorf Cecilia, Glatting Gerhard, Chiesa Carlo, Lindén Ola, Flux Glenn, EANM Dosimetry Committee guidelines for bone marrow and whole-body dosimetry, 10.1007/s00259-010-1422-4
  21. Lassmann M, Chiesa C, Flux G, Bardiès M, EANM Dosimetry Committee, et al. EANM Dosimetry Committee guidance document: good practice of clinical dosimetry reporting. Eur J Nucl Med Mol Imaging 2011;38:192–200. doi: 10.1007/s00259-010-1549-3
  22. Walrand Stéphan, Jamar François, Mathieu Isabelle, Camps Joëlle, Lonneux Max, Sibomana Mérence, Labar Daniel, Michel Christian, Pauwels Stanislas, Quantitation in PET using isotopes emitting prompt single gammas: application to yttrium-86, 10.1007/s00259-002-1068-y
  23. Walrand S. H., van Elmbt L. R., Pauwels S., A non-negative fast multiplicative algorithm in 3D scatter-compensated SPET reconstruction, 10.1007/bf01254478
  24. Cristy M, Active bone marrow distribution as a function of age in humans, 10.1088/0031-9155/26/3/003
  25. Stabin M. G., Eckerman K. F., Bolch W. E., Bouchet L. G., Patton P. W., Evolution and Status of Bone and Marrow Dose Models, 10.1089/108497802760363213
  26. Shih Wei-Jen, Van Wyk Charl, Tc-99m depreotide SPECT demonstrates photon-deficiency in the thoracic vertebrae after adjunct radiation therapy of lung cancer: Correlation with MRI and bone scintigraphy, 10.1007/bf02990029
  27. Tokita Naoki, Hasegawa Shinji, Maruyama Kaoru, Izumi Tohru, Blankenberg Francis G., Tait Jonathan F., Strauss William H., Nishimura Tsunehiko, 99mTc-Hynic-annexin V imaging to evaluate inflammation and apoptosis in rats with autoimmune myocarditis, 10.1007/s00259-002-1006-z
  28. Hauser W., Atkins H. L., Nelson K. G., Richards P., Technetium-99m DTPA: A New Radiopharmaceutical for Brain and Kidney Scanning, 10.1148/94.3.679
  29. Moerlein S.M., Welch M.J., The chemistry of gallium and indium as related to radiopharmaceutical production, 10.1016/0047-0740(81)90034-6
  30. Stern HS, Goodwin DA, Scheffel D, Wagner HN, Kramer HH. In 113m for blood-pool and brain scanning. Nucleonics 1967;25:62–8.
  31. KROLL HARRY, KORMAN SAMUEL, SIEGEL ELSIE, HART HIRAM E., ROSOFF BETTY, SPENCER HERTA, LASZLO DANIEL, Excretion of Yttrium and Lanthanum Chelates of Cyclohexane 1,2-Trans Diamine Tetraacetic Acid and Diethylenetriamine Pentaacetic Acid in Man, 10.1038/180919b0
  32. Jeffcoat MK, McNeil BJ, Davis MA. Indium and iron as tracers for erythroid precursors. J Nucl Med 1978;19:496–500.
  33. Goodwin DA, Sundeberg MW, Diamanti C et al. 111In-labeled radiopharmaceuticals and their clinical use. In: Subramanian G, Rhodes BA, Cooper JF, Sood VJ, editors. Radiopharmaceuticals. New York: The Society of Nuclear Medicine; 1975. p. 80.
  34. Welch MJ, Welch TJ. Solution chemistry of carrier-free indium. In: Subramanian G, Rhodes BA, Cooper JF, Sood VJ, editors. Radiopharmaceuticals. New York: The Society of Nuclear Medicine; 1975. p. 73.
  35. Breeman Wouter A., van der Wansem Katy, Bernard Bert F., van Gameren Arthur, Erion Jack L., Visser Theo J., Krenning Eric P., de Jong M., The addition of DTPA to [177Lu-DOTA0,Tyr3]octreotate prior to administration reduces rat skeleton uptake of radioactivity, 10.1007/s00259-002-1054-4
  36. Oomen S, Somatostatin is a selective chemoattractant for primitive (CD34+) hematopoietic progenitor cells, 10.1016/s0301-472x(01)00772-x
  37. Skikne Barry S., Serum transferrin receptor, 10.1002/ajh.21279